| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|
| ||||||||||||||||||||||||||||||||
1 Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Claude D. Pepper Older Americans Independence Center and Roena Kulynych Center for Memory and Cognition Research, Sticht Center on Aging, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
2 Department of Medicine, Division of Geriatrics, University of Pittsburgh Institute on Aging, Pennsylvania.
3 Intramural Research Program, National Institute on Aging, Baltimore and Bethesda, Maryland.
4 Division of Public Health Sciences and 5 Department of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
6 Department of Geriatrics and Aging Research, University of Florida, Gainesville.
Departments of 7 Epidemiology and Biostatistics and 8 Psychiatry, Neurology and Epidemiology, University of California, San Francisco.
9 Department of Preventive Medicine, University of Tennessee College of Medicine, Memphis.
Address correspondence to Hal H. Atkinson, MD, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157. E-mail: hatkinso{at}wfubmc.edu
|
A |
|---|
|
|
|---|
Methods. Measures of global cognitive function (Modified Mini Mental State Examination [3MS]) and executive control function (ECF) (a clock drawing task [CLOX 1] and the 15-item Executive Interview [EXIT 15]) were obtained in the Health, Aging, and Body Composition Study in 1999–2000. Gait-speed (meters/second) was assessed over 20 meters at usual pace. Using a mixed model, we assessed the relationship between baseline cognitive function and gait-speed change over 3 years.
Results. Two thousand, three hundred forty-nine older adults (mean age 75.6 ± 2.9 years) completed the assessments. After adjustment for baseline gait speed, a 1-standard-deviation (SD) lower performance on each cognitive test was associated with greater gait-speed decline over 3 years: 0.016 m/s for the 3MS (SD = 8.1), 0.009 m/s for CLOX 1 (SD = 2.4), and 0.012 m/s for EXIT 15 (SD = 4.1) (p <.0005 for all). After adjustment for comorbidities, the effect size was attenuated for 3MS and CLOX 1, and the association for EXIT 15 was no longer significant. Depression score was most strongly associated with the EXIT 15 effect reduction.
Conclusion. Global and executive cognitive functions predict declines in gait speed. The association of ECF with gait speed decline is attenuated by comorbid conditions, particularly depression. Elucidation of the mechanisms underlying these associations may point to new pathways for the treatment of physical decline associated with diminished cognitive function.
Cross-sectional studies have found a variety of cognitive function measures to be associated with various aspects of physical performance (7–10,12). Whether the observed relationship between cognitive and physical functioning signifies a parallel decline process or a reciprocal relationship requires longitudinal investigation. Existing longitudinal studies (6,11,13–17) have been limited by sample size, available covariates, selectivity of study participants, and/or reliance on global tests of cognitive function only. Executive control function (ECF) involves attention, inhibition of distracting stimuli, and planning and execution of tasks. Recent research suggests that ECF mediates the stability and velocity of gait in older adults when interference is introduced during walking (18–20). However, ECF may also be an important predictor of subsequent declines in simple physical performance measures through its role in maintaining attention to walking and inhibiting distracting stimuli in older adults aging with comorbid conditions.
To gain a more complete understanding of the relationship between specific cognitive domains including executive function and physical performance decline, the present study examines the relationship between global cognitive function and two measures of executive control and decline in usual gait speed over 3 years in participants in the Health, Aging and Body Composition (Health ABC) study.
| METHODS |
|---|
|
|
|---|
Because ECF testing first occurred at the third annual visit that took place in 1999–2000, this visit was considered the study baseline. A total of 2505 participants had a clinic visit in year 3. Of this group, 2349 completed all cognitive and gait speed tests in 1999–2000 and had at least one gait speed measurement over the subsequent 3-year period. Compared to included participants, excluded participants were older (76.1 ± 2.6 years vs 75.6 ± 2.9 years), more likely to be men (52% vs 44%), and more likely to be black (53% vs 37%). Additionally, excluded participants were less educated, had slower baseline gait speed, and had poorer scores on all three cognitive tests.
Cognitive Tests
At the 1999–2000 visit, global cognitive function was measured using the Modified Mini-Mental Status Examination (3MS) (21). ECF was assessed with a scored clock drawing task (CLOX 1) (22) and the 15-item Executive Interview (EXIT 15), a shortened version of the 25-item Executive Interview (23) developed for the Health ABC study. The 3MS is an expanded version of the Mini-Mental State Examination (24), with additional items assessing verbal fluency, delayed recall, and abstract reasoning. Scores can range from 0 to 100 points; lower scores indicate poorer performance. In the CLOX 1 test, participants are given a blank sheet of paper and are instructed to "draw a clock that says 1:45" and "set the numbers and face of the clock so that a child can read them" (22). The task is then scored from 0 to 15; lower scores indicate poorer performance. The EXIT 15 assesses several ECFs such as inhibition of automatic responses and intrusions, word and design fluency, and sequencing tasks. The test is scored from 0 to 30; lower scores indicate better performance. We chose to include these two measures of ECF although they were significantly correlated in our sample (r =.39), because clock drawing tasks represent a single task that is easy to complete and are often included in clinical practice, whereas the EXIT 15 provides a more lengthy compendium of other ECF tasks.
Gait Speed Assessment
Gait speed was assessed over a 20-meter straight course set up in a corridor. Participants were instructed to begin walking at their usual pace from the starting point and to continue just past an orange cone indicating the end of the course. Timing began at the first footfall over the starting line and ended with the first footfall over the finishing line.
Covariates
In addition to clinic site and baseline gait speed, we considered as possible covariates demographic variables (age, race, sex, educational level, literacy level); health habits (smoking, exercise in the previous week); comorbid conditions, risk factors, and medications (visual impairment, depressive symptoms, body mass index [BMI], hypertension, diabetes, cardiovascular disease, cerebrovascular disease, peripheral arterial disease, and medications including anxiolytic/sleep aids, anti-Parkinson drugs, antidepressants, and cholinesterase inhibitors); and interim health events (falls and hospitalizations). All time-dependent variables were assessed at the 1999–2000 visit except ankle–arm index and height, which were measured 2 years previously at the 1997–1998 visit. Presence of comorbid conditions was obtained from participant reports from the 1997–1998 through 1999–2000 visits. Hospitalizations and falls over the 3-year period of this analysis were assessed by self- or proxy report at each follow-up.
Literacy was assessed using the Rapid Estimate of Adult Literacy in Medicine (REALM) (25). Exercise level was assessed by questionnaire, and the metabolic equivalents of each activity were assigned to calculate the total kilocalories per kilogram body weight expended in the previous week (26). Depressive symptom severity was assessed using the Centers for Epidemiologic Studies of Depression 10-item scale (CESD-10) (27). The ratio of the lower of two systolic blood pressures obtained in the ankle to the systolic blood pressure of the right arm was used to calculate ankle–arm index. BMI was determined from measured weight in kilograms divided by measured height in meters squared. Medications of interest were classified according to the Iowa Drug Information System (IDIS) (28) codes as follows: anxiolytics/sleep aids (codes 28240202–28240276 or 28240834), anti-Parkinson drugs (codes 12080802–12080806 or 28280002–28280013), antidepressants (codes 28160415, 28160434, 28160458, 28160486, or 28160500–28160711) and cholinesterase inhibitors (28200039).
Statistical Analysis
All results are reported as mean ± standard deviation unless otherwise stated. For descriptive statistics according to quartiles of global cognition, we used a chi-square test for binary variables and analysis of variance for continuous variables to compare groups. To assess the relationship between cognitive function and gait speed decline, we first examined gait speed decline according to quartiles of baseline cognitive function for each test, adjusted for baseline gait speed, age, race, and clinic site. Separate mixed-effects models (SAS Proc Mixed) were used to assess the relationship between each independent cognitive variable (3MS, CLOX 1, and EXIT 15) at baseline and gait speed decline over the following 3 years. All models included clinic site as a random effect and baseline gait speed as a fixed effect. A model was also fit controlling for demographics, health habits, comorbid conditions, risk factors, and interim health events. After this analysis, further reduced models were fit in a series of four models. The first included site and baseline gait speed. The second added age, race, education, sex, and the REALM score. The third added exercise level, BMI, visual acuity
20/50, interim hospitalizations, interim falls, CESD-10 score, and medications. The fourth added smoking status, hypertension, diabetes, cerebrovascular disease, coronary artery disease, and peripheral arterial disease. This was done to assess which covariates diminished the relationship between cognition and gait speed decline. A backward elimination procedure from the full model was also performed to determine the impact of each variable in reducing the association of ECF with gait speed decline. All analyses were performed using SAS software (version 8.2; SAS Institute, Cary, NC).
| RESULTS |
|---|
|
|
|---|
|
|
|
of 0.10.
|
80 (n = 2106); these associations remained. | DISCUSSION |
|---|
|
|
|---|
The present study adds to the growing body of longitudinal studies examining the relationship of cognition and physical performance in older adults (6,11,13–15), suggesting a role for cognitive function in preventing a decline in motor task performance over time. We offer a few explanations for the apparent influence of cognitive function on gait speed decline. First, maintenance of an efficient gait may require specific cognitive capacities. Memory, visuospatial skills, cognitive processing speed, and ECFs (such as sustaining attention and inhibiting distraction) may be differentially important to the planning, initiating, and maintaining of walking. A recent small study using functional magnetic resonance imaging indicated greater cognitive monitoring of movements in old adults versus young adults (29), possibly due to sensory declines. Secondly, cognition may be associated with physical performance decline through common pathologies affecting both higher order cognitive functions and physical performance, such as vascular or degenerative lesions.
The significant reduction in the association between the EXIT 15 and gait speed decline following adjustment for covariates was unexpected. The association between CLOX 1 and gait speed decline was also attenuated, but not to the same extent. It is possible that the EXIT 15 measures a broader range of executive functions that are more sensitive to comorbidity. It is likely that multiple, potentially modifiable factors are related to both cognitive and physical function. For example, previous studies have specifically shown relationships between vascular risk and both cognitive and physical function in older adults (30,31). Including depressive symptoms had the greatest impact on reducing the association between EXIT 15 performance and gait speed decline in our model. Previous studies have found an independent association between depressive symptoms and both physical performance declines (32,33) and cognitive decline and impairment (34–36). Fatigue, a common symptom of depression, may affect gait and cognitive performance, and executive control might also be differentially affected because it may require more effort than other cognitive functions, although our data do not allow us to test this hypothesis. Another study provides evidence of an interaction between the Mini-Mental State Examination (24) and the 20-item CESD on subsequent physical performance (11). It is also possible that lower executive function, depressive symptoms, and slower gait may be linked by underlying subcortical vascular disease (31); however, we were unable to address this possibility directly without brain imaging.
This study has several strengths, including a large community-representative study population, longitudinal design, the examination of both global cognitive function and ECF, use of a well-established objective measure of lower extremity physical performance that predicts functional limitations (37,38), and availability of important covariates. There are also several limitations. First, because participants in Health ABC are high functioning, our findings cannot be generalized to more frail populations. Second, the high mean scores on cognitive testing reflect a ceiling effect, which might account for the small magnitude of changes in gait speed that were observed. Although the assessments in Health ABC are detailed, this study is also limited by a lack of physical assessments for parkinsonism. Additionally, the 3MS, CLOX 1, and EXIT 15 all include test components that require good motor function (e.g., drawing pentagons or completing hand movement sequences), which may blur the distinction between the two realms of function studied. Nonetheless, many of the tasks on the 3MS and EXIT 15 involve no motor skills, and none of the motor tasks involve the lower extremities.
Summary
This study provides further evidence that cognitive function is associated with subsequent decline in physical performance in late life. Future research should focus on which aspects of cognitive function are most associated with physical decline and clarification of the mechanisms underlying the association. Further investigation of the complex relationships between cognitive function, physical performance decline, and comorbidities may point to new pathways for the treatment of physical decline associated with diminished cognitive function.
|
A |
|---|
|
|
|---|
The investigators retained full independence in the conduct of this research.
Analyses from this article were presented at The Gerontological Society of America Annual Meeting in November 2004 and at the American Geriatrics Society Meeting in May 2005.
|
F |
|---|
|
|
|---|
Received June 30, 2006
Accepted November 8, 2006
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. M. Hausdorff, A. Schweiger, T. Herman, G. Yogev-Seligmann, and N. Giladi Dual-Task Decrements in Gait: Contributing Factors Among Healthy Older Adults J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2008; 63(12): 1335 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Volpato, M. Cavalieri, G. Guerra, F. Sioulis, M. Ranzini, C. Maraldi, R. Fellin, and J. M. Guralnik Performance-Based Functional Assessment in Older Hospitalized Patients: Feasibility and Clinical Correlates J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2008; 63(12): 1393 - 1398. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Royall SLIPPERY SLOPES J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2008; 63(1): 107 - 107. [Full Text] [PDF] |
||||
![]() |
H. H. Atkinson AUTHORS' RESPONSE TO ROYALL LETTER J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2008; 63(1): 107 - 108. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||
| HOME | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|---|